글로벌 렌녹스-가스토 증후군 약물 시장 – 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 글로벌 Lennox-Gastaut 증후군 약물 시장

렌녹스-가스토 증후군 약물 시장은 2021년에서 2028년까지의 예측 기간 동안 4.6%의 잠재적 성장률을 기록할 것으로 예상되며 2028년까지 9억 3,360만 달러에 도달할 가능성이 높습니다. 연구 개발 활동의 증가가 시장 성장의 원인입니다.

렌녹스-가스토 증후군은 소아 간질성 뇌병증이나 소아 간질 증후군으로도 알려져 있으며, 정신 지체, 다발성 강직-간대 발작, 지능 저하 및 뇌파 검사에서 이상 소견이 나타나는 질환입니다.

LGS 위험 요인이 있는 인구의 급속한 증가는 2021년에서 2028년의 예측 기간 동안 시장 성장을 가속화할 것으로 예상됩니다. 마찬가지로 뇌염 및 뇌막염을 포함한 감염성 질환의 유병률 증가와 생명공학 및 제약 산업의 높은 투자도 렌녹스-가스토 증후군 약물 시장 성장을 강화할 것으로 예측됩니다. 나아가 정부 와 비정부 기구가 이 질환에 대한 사람들의 인식을 높이기 위해 취한 다양한 이니셔티브 도 시장 성장률을 견인할 것으로 예상됩니다.

또한, 의료비 지출 증가, 연구개발 이니셔티브 확대, 정부의 호의적인 지원으로 인해 2021년부터 2028년까지의 예측 기간 동안 렌녹스-가스토 증후군 약물 시장 성장에 영향을 미칠 다양한 새로운 기회가 창출될 가능성이 높습니다.

그러나 이용 가능한 치료법과 관련된 다양한 부작용과 높은 치료 비용은 렌녹스-가스토 증후군 약물 시장 성장을 저해하는 주요 요인으로 작용할 것으로 예상되며, 원격 지역에서 필수 서비스를 이용할 수 없는 것은 위에 언급된 예측 기간 동안 타겟 시장 성장을 더욱 어렵게 만들 수 있습니다.

This lennox-gastaut syndrome drug market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the lennox-gastaut syndrome drug market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Lennox-Gastaut Syndrome Drug Market Scope and Market Size

Lennox-gastaut syndrome drug market is segmented on the basis of drug type, therapy, route of administration, distribution channel and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• Based on drug type, the lennox-gastaut syndrome drug market can be segmented into CNS depressants, anticonvulsants, perampanel, cannabidiol, NRP-2945 others. Others have further been segmented into valproic acid, lamotrigine, topiramate, felbamate, zonisamide and vigabtrin. 
• The therapy segment of the lennox-gastaut syndrome drug market can be segmented into medication, surgery, intravenous immunoglobulin therapy and ketogenic diet products.
• On the basis of route of administration, the lennox-gastaut syndrome drug market can be segmented into oral and parenteral.
• Based on distribution channel, the lennox-gastaut syndrome drug market can be segmented into hospital pharmacy, retail pharmacy and online pharmacy.
• On the basis of end user, the lennox-gastaut syndrome drug market can be segmented into hospitals, homecare, specialty clinics and others.

Lennox-Gastaut Syndrome Drug Market Country Level Analysis

Lennox-gastaut syndrome drug market is analyzed and market size information is provided by country by drug type, therapy, route of administration, distribution channel and end user as referenced above.

The countries covered in the lennox-gastaut syndrome drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America leads the lennox-gastaut syndrome drug market due to the high research and development activities in the neurology field and strong presence of pharmaceutical industries. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of the rise in the government support and increased number of prevalence cases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Lennox-gastaut syndrome drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Lennox-Gastaut Syndrome Drug Market Share Analysis

Lennox-gastaut syndrome drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to lennox-gastaut syndrome drug market.

The major players covered in the lennox-gastaut syndrome drug market report are Pfizer Inc., Sunovion Pharmaceuticals Inc., Novartis AG, Abbott, Eisai Co., Ltd, INSYS THERAPEUTICS, INC., GW Pharmaceuticals plc, Johnson & Johnson Services, Inc, GlaxoSmithKline plc, Zogenix, H. Lundbeck A/S, Bausch Health Companies Inc., Supernus Pharmaceuticals, Inc., Sanofi, Marinus Pharmaceuticals, Inc., GW Pharmaceuticals plc and Teva Pharmaceutical Industries Ltd., among other domestic and global players. Lennox-gastaut syndrome drug market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-46286